tranylcypromine has been researched along with Leukemia, Myeloid, Acute in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (42.86) | 24.3611 |
| 2020's | 4 (57.14) | 2.80 |
| Authors | Studies |
|---|---|
| Amaral, FMR; Chadwick, JA; Deb, G; Leong, HS; Maes, T; Maiques-Diaz, A; Somervaille, TCP; Spencer, GJ; Williams, EL; Wingelhofer, B | 1 |
| Cen, M; Du, Y; Ganesan, A; Huang, P; Liang, L; Luo, B; Meng, N; Wang, H; Wen, S | 1 |
| Besenbeck, B; Binder, M; Bornhäuser, M; Burhenne, J; Dugas, M; Foerster, KI; Göllner, S; Göthert, JR; Haefeli, WE; Lenz, G; Mikesch, JH; Müller, LP; Müller-Tidow, C; Mundmann, P; Noppeney, R; Pabst, C; Platzbecker, U; Röllig, C; Schlenk, RF; Schliemann, C; Serve, H; Wass, M; Wermke, M | 1 |
| Bradley, TJ; Chen, C; Cimmino, L; Dinh, Y; Kwon, D; Morey, L; Perez, A; Santos, HGD; Shiekhattar, R; Swords, RT; Tayari, MM; Thomassen, A; Watts, JM; Zelent, A | 1 |
| Abou-El-Ardat, K; Barth, J; Berg, T; Bug, G; Dalic, D; Greve, G; Jung, M; Khandanpour, C; Kurrle, N; Lübbert, M; Maier, AM; Metzger, E; Mohr, S; Schmitt, M; Schüle, R; Schulz-Fincke, J; Schütte, J; Serve, H; Tosic, M; Vassen, L; Wagner, SA | 1 |
| Cockerill, MJ; Hitchin, JR; Lynch, JT; Somervaille, TC; Wiseman, DH | 1 |
| Burnett, A; Casero, RA; Chen, WC; Dick, JE; Dugas, M; Göllner, S; Hebestreit, K; Howell, L; Jin, L; Klein, HU; Marton, L; Mills, K; Minden, MD; Müller-Tidow, C; Petrie, K; Popescu, AC; Schenk, T; Wang, JC; Woster, P; Zelent, A | 1 |
2 trial(s) available for tranylcypromine and Leukemia, Myeloid, Acute
| Article | Year |
|---|---|
A proof of concept phase I/II pilot trial of LSD1 inhibition by tranylcypromine combined with ATRA in refractory/relapsed AML patients not eligible for intensive therapy.
Topics: Adult; Aged; Antidepressive Agents; Antineoplastic Agents; Arabidopsis Proteins; DNA-Binding Proteins; Drug Resistance, Neoplasm; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Proof of Concept Study; Prospective Studies; Salvage Therapy; Survival Rate; Transcription Factors; Tranylcypromine; Tretinoin; Young Adult | 2021 |
Clinical Responsiveness to All-trans Retinoic Acid Is Potentiated by LSD1 Inhibition and Associated with a Quiescent Transcriptome in Myeloid Malignancies.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Female; Gene Expression Regulation, Leukemic; Histone Demethylases; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Transcriptome; Tranylcypromine; Tretinoin | 2021 |
5 other study(ies) available for tranylcypromine and Leukemia, Myeloid, Acute
| Article | Year |
|---|---|
Pre-clinical activity of combined LSD1 and mTORC1 inhibition in MLL-translocated acute myeloid leukaemia.
Topics: Animals; Antidepressive Agents; Antineoplastic Agents; Apoptosis; Cell Proliferation; Drug Therapy, Combination; Everolimus; Female; Gene Expression Regulation, Leukemic; Histone Demethylases; Histone-Lysine N-Methyltransferase; Humans; Leukemia, Myeloid, Acute; Mechanistic Target of Rapamycin Complex 1; Mice; Mice, Inbred NOD; Mice, SCID; Myeloid-Lymphoid Leukemia Protein; Translocation, Genetic; Tranylcypromine; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2020 |
New tranylcypromine derivatives containing sulfonamide motif as potent LSD1 inhibitors to target acute myeloid leukemia: Design, synthesis and biological evaluation.
Topics: Antineoplastic Agents; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Design; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Histone Demethylases; Humans; Leukemia, Myeloid, Acute; Molecular Structure; Structure-Activity Relationship; Sulfonamides; Tranylcypromine; Tumor Cells, Cultured | 2020 |
LSD1 inhibition by tranylcypromine derivatives interferes with GFI1-mediated repression of PU.1 target genes and induces differentiation in AML.
Topics: Animals; Antidepressive Agents; Cell Differentiation; DNA-Binding Proteins; Gene Expression Regulation, Leukemic; Histone Demethylases; Humans; Interferon Regulatory Factors; Leukemia, Myeloid, Acute; Mice; Mice, Knockout; Neoplastic Stem Cells; Proto-Oncogene Proteins; Trans-Activators; Transcription Factors; Tranylcypromine; Tumor Cells, Cultured | 2019 |
CD86 expression as a surrogate cellular biomarker for pharmacological inhibition of the histone demethylase lysine-specific demethylase 1.
Topics: B7-2 Antigen; Biomarkers; Cell Line, Tumor; Dose-Response Relationship, Drug; Enzyme Inhibitors; Histone Demethylases; Humans; Leukemia, Myeloid, Acute; Structure-Activity Relationship; Tranylcypromine; Up-Regulation | 2013 |
Inhibition of the LSD1 (KDM1A) demethylase reactivates the all-trans-retinoic acid differentiation pathway in acute myeloid leukemia.
Topics: Animals; Antigens, CD34; Apoptosis; CD11b Antigen; Cell Differentiation; Cells, Cultured; Cytokines; Disease Models, Animal; Drug Interactions; Enzyme Inhibitors; Female; Flow Cytometry; Gene Expression Regulation; Histone Demethylases; Humans; Leukemia, Myeloid, Acute; Lysine; Mice; Mice, Inbred NOD; Mice, SCID; RNA, Small Interfering; Stem Cell Factor; Time Factors; Transplants; Tranylcypromine; Tretinoin | 2012 |